샘플 요청 목록

 카트 문의
시장보고서
상품코드
1888810

동물용 안과 의약품 시장 규모, 점유율 및 동향 분석 보고서 : 동물별, 약제별, 적응증별, 유통경로별, 지역별, 부문 예측(2025-2033년)

Veterinary Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Animal, By Drug, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

동물용 안과 의약품 시장 요약

세계의 동물용 안과 의약품 시장 규모는 2024년에 19억 5,000만 달러로 추정되며, 2033년까지 36억 달러에 이를 것으로 예측됩니다.

또한 2025년부터 2033년까지 7.00%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다. 시장 성장을 견인하는 요인으로는 안과용 약물 전달 기술의 발전, 장시간 작용하는 안과 치료법 개발 증가, 항균제의 올바른 사용과 근거에 기반한 사용에 대한 관심 증가, 복잡한 안과 질환 치료에 대한 임상 수요 증가 등을 꼽을 수 있습니다.

약물 전달 기술의 발전이 시장 성장을 주도하고 있습니다. 2025년 4월 예루살렘 히브리대학교에서 실시한 연구에 따르면, 가교 히알루론산(XHA)을 사용한 점안제가 기존 제제보다 더 나은 결과를 얻었습니다고 합니다. 구체적으로, XHA 기반 점안제로 치료한 개는 폴리비닐 알코올을 사용한 점안제 대비 세파졸린에 대한 노출량이 2.4배, 클로람페니콜에 대한 노출량이 4.2배 더 높았습니다. 이러한 개선은 약물 농도가 높고 안구 표면에 머무르는 시간이 길어져 투약 횟수가 줄어들고 반려동물 보호자의 순응도가 높아진다는 점에서 매우 중요합니다. 투약 부담의 감소는 동물의료 현장에서 고부가가치 안과용 약품의 매력을 높입니다.

또한, 2025년 4월 drugs.com의 기사에서 히알루론산 캐리어가 항생제가 개 눈에 머무는 시간을 연장시켜 항생제 내성 위험을 감소시킬 수 있다고 설명하면서 이 결과를 뒷받침하고 있습니다. 히알루론산 자체에 살균 작용이 있어 눈 조직의 치유를 촉진하는 점 또한 주목할 만합니다. 그 결과, 동물용 의약품 제조업체들은 항생제와 XHA와 같은 첨단 운반체 기술을 결합한 안과용 제제 개발의 가능성을 발견하고 있습니다. 이는 안구 감염에 대한 치료 효과를 높이는 동시에, 항진균제, 면역조절제, 항녹내장제 등 새로운 카테고리의 항진균제, 면역조절제, 항녹내장제 등의 새로운 카테고리로 나아갈 수 있는 길을 열어줄 것입니다.

결론적으로, 약제 노출량 향상, 투여 빈도 감소, 치료 효과 개선을 실현하는 기술이 수의용 안과 치료제 수요를 견인하고 있습니다. 동물병원에서는 보다 효과적이고 보호자의 부담이 적은 제제를 선호합니다. 이에 제조업체들은 전달 시스템의 혁신으로 대응하고 있으며, 그 결과 동물용 안과 시장은 더욱 강력하게 성장하고 있습니다.

자주 묻는 질문

  • 동물용 안과 의약품 시장 규모는 어떻게 예측되나요?
  • 동물용 안과 의약품 시장 성장을 이끄는 요인은 무엇인가요?
  • 가교 히알루론산(XHA)을 사용한 점안제의 장점은 무엇인가요?
  • 히알루론산 캐리어의 역할은 무엇인가요?
  • 동물병원에서 선호하는 안과용 제제의 특징은 무엇인가요?
  • 동물용 안과 의약품 시장의 주요 기업은 어디인가요?

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 동물용 안과 의약품 시장 변동 동향과 범위

  • 시장 계통 전망
    • 상위 시장
    • 관련 시장
  • 시장 역학
  • 동물용 안과 의약품 시장 분석 툴
    • Porter의 Five Forces 분석
    • PESTEL 분석(SWOT 분석에 의한다)
    • 지역별·주요 유형별에 의한 추정 동물 인원수(2024년)

제4장 동물용 안과 의약품 시장 : 동물별, 추정 및 동향 분석

  • 동물용 안과 의약품 시장 : 동물별 변동 분석
  • 동물별 동물용 안과 의약품 시장 규모와 동향 분석(2021년-2033년)
  • 개
  • 고양이
  • 말
  • 소
  • 기타 동물

제5장 동물용 안과 의약품 시장 : 약제별, 추정 및 동향 분석

  • 동물용 안과 의약품 시장 : 약제별 변동 분석
  • 동물용 안과 의약품 시장 규모와 동향 분석(약제별, 2021년-2033년)
  • 항생제
  • 비스테로이드성 항염증제(NSAIDs)
  • 코르티코스테로이드
  • 윤활유 및 인공누액
  • 진통제 및 통증 완화제
  • 기타 약제

제6장 동물용 안과 의약품 시장 : 적응증별 추정·동향 분석

  • 동물용 안과 의약품 시장 : 적응증별 변동 분석
  • 동물용 안과 의약품 시장 규모와 동향 분석(적응증별, 2021년-2033년)
    • 안검 이상
    • 백내장
    • 녹내장
    • 포도막염
    • 결막염
    • 각막 합병증
    • 기타 적응증

제7장 동물용 안과 의약품 시장 : 유통 채널별, 추정 및 동향 분석

  • 동물용 안과 의약품 시장 : 유통 채널별 변동 분석
  • 유통 채널별 동물용 안과 의약품 시장 규모와 동향 분석(2021년-2033년)
    • 동물 병원 및 진료소
    • 전문점
    • 전자상거래
    • 기타 유통 채널

제8장 동물용 안과 의약품 시장 : 지역별, 추정 및 동향 분석

  • 지역별 대시보드
  • 지역별 동물용 안과 의약품 시장 점유율(2024년 및 2033년)
  • 지역별 전망
  • 북미
    • 미국
    • 캐나다
    • 멕시코
  • 유럽
    • 영국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 덴마크
    • 스웨덴
    • 노르웨이
  • 아시아태평양
    • 일본
    • 중국
    • 인도
    • 호주
    • 한국
    • 태국
  • 라틴아메리카
    • 브라질
    • 아르헨티나
  • 중동 및 아프리카
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 쿠웨이트
    • 카타르
    • 오만

제9장 경쟁 구도

  • 시장 진출기업 분류
  • 기업별 시장 현황 분석/히트맵 분석
  • 기업 개요
    • Merck &Co., Inc.
    • Zoetis
    • Dechra Pharmaceuticals
    • Virbac
    • Ceva Sante Animale
    • Elanco
    • Bausch &Lomb
    • Sandoz
    • Norbrook Laboratories
    • I-Med Animal Health
LSH 26.01.05

Veterinary Ophthalmic Drugs Market Summary

The global veterinary ophthalmic drugs market size was estimated at USD 1.95 billion in 2024 and is projected to reach USD 3.60 billion by 2033, growing at a CAGR of 7.00% from 2025 to 2033. Some of the factors driving the market growth are advancements in ophthalmic drug-delivery technologies, rising development of long-acting ophthalmic therapies, increasing focus on antimicrobial stewardship & evidence-based use, and growing clinical demand for treatment of complex ocular diseases.

Advances in drug-delivery technology are driving market growth. An April 2025 study at the Hebrew University of Jerusalem found that eyedrops using cross-linked hyaluronic acid (XHA) achieved better results than traditional formulations. Specifically, dogs treated with XHA-based drops had 2.4 times greater exposure to cefazolin and 4.2 times greater exposure to chloramphenicol compared to drops using polyvinyl alcohol. This improvement matters because higher drug concentration and longer retention on the ocular surface mean fewer doses and better compliance among pet owners. Lower dosing burden increases the appeal of premium ophthalmic drugs in veterinary practice.

Moreover, another April 2025 drugs.com article confirmed this finding, explaining that the hyaluronic acid carrier allowed antibiotics to stay longer on canine eyes and suggested a reduced risk of antibiotic resistance. It is noted that hyaluronic acid itself has antiseptic properties and supports the healing of eye tissues. As a result, veterinary pharmaceutical firms see an opportunity in developing ophthalmic formulations that combine antibiotics with advanced carriers like XHA. These deliver better outcomes for eye infections and open the door for new categories, such as anti-fungal, immunomodulators, and anti-glaucoma agents with similar delivery enhancements.

To conclude, technology that boosts drug exposure, reduces frequency of dosing, and improves therapeutic effect is pushing demand for veterinary eye-care drugs. Veterinary clinics prefer formulations that work better and require less owner effort. Manufacturers respond by innovating delivery systems. The net effect is stronger growth in the veterinary ophthalmology market.

Global Veterinary Ophthalmic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global veterinary ophthalmic drugs market report based on animal, drug, indication, distribution channel, and region:

  • Animal Outlook (Revenue, USD Million, 2021 - 2033)
  • Canine
  • Feline
  • Equine
  • Bovine
  • Others
  • Drug Outlook (Revenue, USD Million, 2021 - 2033)
  • Antibiotics
  • NSAIDs
  • Corticosteroids
  • Lubricants/Artificial Tears
  • Analgesics/Pain Relievers
  • Others Drugs
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Eyelid Abnormalities
  • Cataract
  • Glaucoma
  • Retinal Complications
  • Uveitis
  • Conjunctivitis
  • Corneal Complications
  • Other Indications
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Veterinary Hospitals & Clinics
  • Specialty Stores
  • E-Commerce
  • Other Distribution Channels
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Qatar
    • Oman

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased Database
    • 1.3.2. GVR's Internal Database
    • 1.3.3. Secondary Sources
    • 1.3.4. Primary Research
  • 1.4. Information/Data Analysis
  • 1.5. Market Formulation & Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis
    • 1.7.2. Global Market: CAGR Calculation
  • 1.8. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Veterinary Ophthalmic Drugs Market Variable Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market
    • 3.1.2. Ancillary Market
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Advancements in Ophthalmic Drug-Delivery Technologies
      • 3.2.1.2. Rising Development of Long-Acting Ophthalmic Therapies
      • 3.2.1.3. Increasing Focus on Antimicrobial Stewardship & Evidence-Based Use
      • 3.2.1.4. Growing Clinical Demand for Treatment of Complex Ocular Diseases
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Regulatory Restrictions on Antibiotic Use in Animals
      • 3.2.2.2. Limited Standardized Guidelines for Ophthalmic Antibiotic Prescribing
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
  • 3.3. Veterinary Ophthalmic Drugs Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis, by SWOT
    • 3.3.3. Estimated Animal Population by region, key species, 2024

Chapter 4. Veterinary Ophthalmic Drugs Market: Animal Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Veterinary Ophthalmic Drugs Market: Animal Movement Analysis
  • 4.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by animal, 2021 to 2033 (USD Million)
  • 4.4. Canine
    • 4.4.1. Canine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Feline
    • 4.5.1. Feline Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Equine
    • 4.6.1. Equine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Bovine
    • 4.7.1. Bovine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.8. Other Animals
    • 4.8.1. Other Animals Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Veterinary Ophthalmic Drugs Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Veterinary Ophthalmic Drugs Market: Drug Movement Analysis
  • 5.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Drug, 2021 to 2033 (USD Million)
  • 5.4. Antibiotics
    • 5.4.1. Antibiotics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. NSAIDs
    • 5.5.1. NSAIDs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Corticosteroids
    • 5.6.1. Corticosteroids Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Lubricants/Artificial Tears
    • 5.7.1. Lubricants/Artificial Tears Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Analgesics/Pain Relievers
    • 5.8.1. Analgesics/Pain Relievers Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Others Drugs
    • 5.9.1. Other Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Veterinary Ophthalmic Drugs Market: By Indication Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Veterinary Ophthalmic Drugs Market: By Indication Movement Analysis
  • 6.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million)
    • 6.3.1. Eyelid Abnormalities
      • 6.3.1.1. Eyelid Abnormalities Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Cataract
      • 6.3.2.1. Cataract Care Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Glaucoma
      • 6.3.3.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
      • 6.3.3.2. Retinal Complications
      • 6.3.3.3. Retinal Complications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.4. Uveitis
      • 6.3.4.1. Uveitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.5. Conjunctivitis
      • 6.3.5.1. Conjunctivitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.6. Corneal Complications
      • 6.3.6.1. Corneal Complications Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.7. Other Indications
      • 6.3.7.1. Other Indications Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Veterinary Ophthalmic Drugs Market: By Distribution Channel Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Veterinary Ophthalmic Drugs Market: By Distribution Channel Movement Analysis
  • 7.3. Veterinary Ophthalmic Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
    • 7.3.1. Veterinary Hospitals & Clinics
      • 7.3.1.1. Veterinary Hospitals & Clinics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. Specialty Stores
      • 7.3.2.1. Specialty Stores Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. E-Commerce
      • 7.3.3.1. E-Commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. Other Distribution Channels
      • 7.3.4.1. Other Distribution Channels Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Veterinary Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Dashboard
  • 8.2. Veterinary Ophthalmic Drugs Market Share, By Region, 2024 & 2033, USD Million
  • 8.3. Regional Outlook
  • 8.4. North America
    • 8.4.1. North America Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Regulatory Framework
      • 8.4.2.4. U.S. Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. Regulatory Framework
      • 8.4.3.4. Canada Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. Regulatory Framework
      • 8.4.4.4. Mexico Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Regulatory Framework
      • 8.5.2.4. UK Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Regulatory Framework
      • 8.5.3.4. Germany Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Regulatory Framework
      • 8.5.4.4. France Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Competitive Scenario
      • 8.5.5.3. Regulatory Framework
      • 8.5.5.4. Italy Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Competitive Scenario
      • 8.5.6.3. Regulatory Framework
      • 8.5.6.4. Spain Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.7. Denmark
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Competitive Scenario
      • 8.5.7.3. Regulatory Framework
      • 8.5.7.4. Denmark Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.8. Sweden
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Competitive Scenario
      • 8.5.8.3. Regulatory Framework
      • 8.5.8.4. Sweden Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.5.9. Norway
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Competitive Scenario
      • 8.5.9.3. Regulatory Framework
      • 8.5.9.4. Norway Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. Regulatory Framework
      • 8.6.2.4. Japan Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Regulatory Framework
      • 8.6.3.4. China Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. Regulatory Framework
      • 8.6.4.4. India Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.5. Australia
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Regulatory Framework
      • 8.6.5.4. Australia Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.6. South Korea
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Competitive Scenario
      • 8.6.6.3. Regulatory Framework
      • 8.6.6.4. South Korea Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Competitive Scenario
      • 8.6.7.3. Regulatory Framework
      • 8.6.7.4. Thailand Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Competitive Scenario
      • 8.7.2.3. Regulatory Framework
      • 8.7.2.4. Brazil Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Competitive Scenario
      • 8.7.3.3. Regulatory Framework
      • 8.7.3.4. Argentina Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
  • 8.8. Middle East & Africa
    • 8.8.1. Middle East & Africa Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Competitive Scenario
      • 8.8.2.3. Regulatory Framework
      • 8.8.2.4. South Africa Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Competitive Scenario
      • 8.8.3.3. Regulatory Framework
      • 8.8.3.4. Saudi Arabia Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Competitive Scenario
      • 8.8.4.3. Regulatory Framework
      • 8.8.4.4. UAE Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Competitive Scenario
      • 8.8.5.3. Regulatory Framework
      • 8.8.5.4. Kuwait Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.6. Qatar
      • 8.8.6.1. Key Country Dynamics
      • 8.8.6.2. Competitive Scenario
      • 8.8.6.3. Regulatory Framework
      • 8.8.6.4. Qatar Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)
    • 8.8.7. Oman
      • 8.8.7.1. Key Country Dynamics
      • 8.8.7.2. Competitive Scenario
      • 8.8.7.3. Regulatory Framework
      • 8.8.7.4. Oman Veterinary Ophthalmic Drugs Market Estimates And Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Market Participant Categorization
  • 9.2. Company Market Position Analysis/ Heat Map Analysis
  • 9.3. Company Profiles
    • 9.3.1. Merck & Co., Inc.
      • 9.3.1.1. Participant's Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Zoetis
      • 9.3.2.1. Participant's Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Dechra Pharmaceuticals
      • 9.3.3.1. Participant's Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. Virbac
      • 9.3.4.1. Participant's Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Ceva Sante Animale
      • 9.3.5.1. Participant's Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Elanco
      • 9.3.6.1. Participant's Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Bausch & Lomb
      • 9.3.7.1. Participant's Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Sandoz
      • 9.3.8.1. Participant's Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Norbrook Laboratories
      • 9.3.9.1. Participant's Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives
    • 9.3.10. I-Med Animal Health
      • 9.3.10.1. Participant's Overview
      • 9.3.10.2. Financial Performance
      • 9.3.10.3. Product Benchmarking
      • 9.3.10.4. Strategic Initiatives
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제